7 / 15
Volume 2, Issue 3 2017
Journal of Medical Oncology and Therapeutics
Dermatologists & Melanoma 2017
August 31-September 01, 2017
Page 77
&
2
nd
Euro-Global Congress on
August 31-September 01, 2017 London, UK
12
th
Global Dermatologists Congress
Melanoma and Skin Diseases
Psoriasis and quality of life
Hülya Çakmur
Kafkas University, Turkey
Background:
Patients with psoriasis experience a low quality of life and high treatment burden.
Objectives:
To assess psoriatic patient quality of life using the Dermatology Life Quality Index (DLQI) in the Northeastern
Anatolia region of Turkey. Additionally, we evaluated the correlation between the DLQI and the clinical severity of psoriasis
and examined demographic data and their relationship with the DLQI and psoriasis severity.
Materials & Methods:
This study was a single-center, prospective, cross-sectional study at the University of Kafkas, Kars,
Turkey. 127 adult patients were included in the study. The Turkish version of the DLQI was used. To measure psoriasis
severity, the Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) were simultaneously evaluated. The patient
demographics were compared with quality of life and the severity of psoriasis.
Results:
DLQI scores ranged from “very large” to “extremely large” in 61% of the patients. The psoriasis severity (BSA and
PASI) was “mild” in 63% of patients. The quality of life was significantly affected in cigarette smokers and in patients whose
disease included nail involvement. The PASI and BSA scores of patients with scalp and nail involvement were significantly
higher. A significant, positive correlation was found between disease duration and the severity of psoriasis. BSA correlated
with PASI.
Conclusion:
The quality of life of psoriasis patients is strongly reduced. A significant relationship was found for DLQI with
nail psoriasis and smoking. A linear, positive correlation was detected between the DLQI and BSA but not between the DLQI
and PASI.
hulyacakmur@gmail.comJ Med Oncl Ther 2017, 2:3